Vol. 6 No. 2S (2012)

Vol. 6 No. 2S (2012)

Published: 2012-12-15

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach

Mario Annunziata

3-5
- PDF

Nilotinib therapy after resistance to imatinib

Raffaele Porrini, Enrico Montefusco

7-10
- PDF
Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk

Ursula Sessa, Maria Celentano, Stefano Rocco, Rossella Fabbricini, Olimpia Finizio, Vincenzo Mettivier

11-14
- PDF
Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML

Giovanni Caocci, Sandra Atzeni, Giorgio La Nasa

15-18
- PDF
Safety and efficacy of nilotinib after 10 years of interferon

Filippo Russo

19-22
- PDF